Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United States of America.


NDAQ:IPA - Post by User

Post by mercedesmanon Nov 30, 2021 9:30am
133 Views
Post# 34179437

Lets fast track this Puppy...

Lets fast track this Puppy...In the past week it has become abundantly clear that the world needs .....exactly what IPA is trying to producc....


...a Polytope multi- Antibody Cocktail


On speculation that this might work, this will move large....

...if the Results of testing (to be released Janaury) live up to even half of their promise, this thing will go crazy !

Our Polytope program continues to exceed internal expectations and we are cautiously optimistic that it will continue to prove effective against all emerging variants, in particular as our Polytope was conceived with this specific purpose in mind," stated Dr. Jennifer Bath, IPA CEO and President. "IPA is fully aware of the global importance of the continued advancement of its proprietary cocktail therapy, and we are happy to share the program remains on track." Dr. Bath added, "FDA feedback on our pre-IND application was very helpful as we entered our pharmacokinetic and toxicological studies and as we continue on our quest to provide a best-in-class COVID therapy."

MM
<< Previous
Bullboard Posts
Next >>